娌涘厭鑲虹値鐞冭弻涓冨児鎺ュ悎鍨嬬柅鑻
Kraj: Tajwan
J臋zyk: chi艅ski
殴r贸d艂o: 琛涚敓绂忓埄閮ㄩ鍝佽棩鐗╃鐞嗙讲 (Ministry of Health and Welfare, Food And Drug Administration)
Ulotka dla pacjenta
(PIL)
17-03-2021
Wys艂a膰 pro艣b臋.
Sk艂adnik aktywny:
POLYSACCHARIDE SEROTYPE;;POLYSACCHARIDE SEROTYPE;;POLYSACCHARIDE SEROTYPE;;POLYSACCHARIDE SEROTYPE;;CRM197 CARRIER PROTEIN;;POLYSACCHARIDE SEROTYPE;;POLYSACCHARIDE SEROTYPE;;OLIGOSACCHARIDE SEROTYPE 18C
Dost臋pny od:
缇庡晢鎯犳皬钘ュ粻锛堜簽娲诧級鑲′唤鏈夐檺鍏徃鍙扮仯鍒嗗叕鍙 鏂板寳甯傛贰姘村崁涓鏉辫矾浜屾177铏 (23984410)
Kod ATC:
J07AL
Forma farmaceutyczna:
娉ㄥ皠鍔
Sk艂ad:
CRM197 CARRIER PROTEIN (1600001310) MCG; POLYSACCHARIDE SEROTYPE (9200022020) (19F)MCG; POLYSACCHARIDE SEROTYPE (9200022020) (23F)MCG; POLYSACCHARIDE SEROTYPE (9200022020) (4)MCG; POLYSACCHARIDE SEROTYPE (9200022020) (6B)MCG; POLYSACCHARIDE SEROTYPE (9200022020) (9V)MCG; POLYSACCHARIDE SEROTYPE (9200022020) (14)MCG; OLIGOSACCHARIDE SEROTYPE 18C (9900016520) MCG
Sztuk w opakowaniu:
鐩掕;;灏忕摱;;闋愬厖寮忔敞灏勯嚌绛
Klasa:
鑿屻鐤
Typ recepty:
闋堢敱閱斧铏曟柟浣跨敤
Wyprodukowano przez:
WYETH PHARMACEUTICALS DIVISION OF WYETH HOLDINGS CORPORATION 401 NORTH MIDDLETOWN RD., PEARL RIVER, NY 10965, U.S.A. US
Dziedzina terapeutyczna:
Pneumococcal vaccines
Wskazania:
闋愰槻鑾㈣啘琛娓呭瀷(4, 6B, 9V, 14, 18C, 19F鍜23F)鐨勮偤鐐庨張鐞冭弻鎵寮曡捣鐨勪镜鍏ユх柧鐥呫
Podsumowanie produktu:
瑷婚姺鏃ユ湡: 2016/05/30; 瑷婚姺鐞嗙敱: 瑷卞彲璀夊凡閫炬湁鏁堟湡; 鏈夋晥鏃ユ湡: 2012/10/07; 鑻辨枃鍝佸悕: PREVENAR, PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE (DIPHTHERIA CRM197 PROTEIN)
Status autoryzacji:
宸茶ɑ閵
Data autoryzacji:
2002-10-07
